Condition (MeSH)
Intractable Pain
ClinicalTrials.gov lists 85 trials for Intractable Pain or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
1 more section with rows
85 of the 85 trials are tagged with Intractable Pain itself; the rest are tagged with a narrower condition beneath it.
When did Intractable Pain trials start? (23)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 10
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 6 |
| 2025 | 2 |
| 2024 | 3 |
| 2023 | 2 |
| 2022 | 6 |
| 2021 | 6 |
| 2020 | 10 |
| 2019 | 6 |
| 2018 | 3 |
| 2017 | 4 |
Showing 10 of 23 earlier years.
No forecast is made for this condition: it averages 3.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 7 trials still running at the 2026-10-09 snapshot; registered median of 22 months across 51 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Intractable Pain trials in? (9)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 3 |
| Phase 1/2 | 3 |
| Phase 2 | 5 |
| Phase 2/3 | 1 |
| Phase 3 | 10 |
| Phase 4 | 7 |
| Not applicable | 37 |
| Observational | 18 |
| Expanded access | 1 |
How many Intractable Pain trials are recruiting? (10)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 4 |
| Recruiting | 9 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 2 |
| Completed | 38 |
Showing 5 of 10 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Intractable Pain trials? (6)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Boston Scientific Corporation | 4 |
| MedtronicNeuro | 4 |
| Abbott Medical Devices | 3 |
| Flowonix Medical | 3 |
| Janssen Pharmaceutical K.K. | 2 |
Showing 5 of 6 sponsors.
Which drugs are being tested for Intractable Pain? (5)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| PMI-150 (intranasal ketamine) | 6 |
| Resiniferatoxin | 3 |
| DEXMEDETOMIDINE | 2 |
| Ziconotide | 2 |
| FENTANYL | 2 |
Interventions as named in the registry (10)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Sedation with Propofol | 2 |
| PCA plus methadone (Experimental) | 1 |
| THC + CBD | 1 |
| Substance P-Saporin | 1 |
| NaCl 0.9% NS | 1 |
Showing 5 of 10 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Intractable Pain trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Infection | 10 | 3 |
| Disease progression | 7 | 1 |
| Lead Migration | 5 | 1 |
| Pneumonia | 4 | 2 |
| hospital stay longer than 24 hours | 4 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Intractable Pain? (321)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| A Phase II Study About Efficacy and Safety of the Continuous IntraVenous Infusion of Ketamine as Adjuvant to Opioids in Terminally Ill Cancer Patients With Refractory Cancer Pain (CIVIK Trial). | The American journal of hospice & palliative care | 2025 | Yes |
| Treatment of Intractable Cancer Pain with Resiniferatoxin - An Interim Study. | NEJM evidence | 2025 | Yes |
| Occipital Nerve Stimulation for Recurrent Trigeminal Neuralgia Without Occipital Pain. | Neuromodulation : journal of the International Neuromodulation Society | 2023 | Yes |
| Precise management system for chronic intractable pain patients implanted with spinal cord stimulation based on a remote programming platform: study protocol for a randomized controlled trial (PreMaSy study). | Trials | 2023 | Yes |
| Availability of and factors related to interventional procedures for refractory pain in patients with cancer: a nationwide survey. | BMC palliative care | 2022 | Yes |
Showing 5 of 321 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.